Patents Represented by Attorney, Agent or Law Firm Craig G. Svoboda
-
Patent number: 6051403Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antagonists and agonists vectors and host cells expressing, and immunoadhesions and antibodies to Nsp1, Nsp2 and Nsp3.Type: GrantFiled: August 4, 1999Date of Patent: April 18, 2000Assignee: Genentech, Inc.Inventors: Timothy A. Stewart, Yanmei Lu
-
Patent number: 6037453Abstract: Two classes of polypeptides derived from human IgE are described. One class binds selectively to the high affinity IgE receptor on mast cells and basophils, but not to the low affinity IgE receptor on B-cells, monocytes, eosinophils and platelets. The other class binds to the low affinity receptor, but not the high affinity receptor. The differential binding polypeptides of this invention are useful in diagnostic procedures for IgE receptors or in the therapy of IgE-mediated disorders such as allergies. They also are useful in preparing antibodies capable of binding regions of IgE that participate in receptor binding.Type: GrantFiled: June 6, 1995Date of Patent: March 14, 2000Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 6022708Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists to human & vertebrate fused.Type: GrantFiled: February 26, 1998Date of Patent: February 8, 2000Assignee: Genentech, Inc.Inventors: Frederic de Sauvage, Arnon Rosenthal
-
Patent number: 5994514Abstract: Two classes of polypeptides derived from human IgE are described. One class binds selectively to the high affinity IgE receptor on mast cells and basophils, but not to the low affinity IgE receptor on B-cells, monocytes, eosinophils and platelets. The other class binds to the low affinity receptor, but not the high affinity receptor. The differential binding polypeptides of this invention are useful in diagnostic procedures for IgE receptors or in the therapy of IgE-mediated disorders such as allergies. They also are useful in preparing antibodies capable of binding regions of IgE that participate in receptor binding.Type: GrantFiled: June 5, 1995Date of Patent: November 30, 1999Assignee: Genentech, Inc.Inventors: Paula M. Jardieu, Leonard G. Presta
-
Patent number: 5994511Abstract: The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of subtituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.Type: GrantFiled: July 2, 1997Date of Patent: November 30, 1999Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
-
Patent number: 5990281Abstract: Novel vertebrate homologues of Smoothened, including human and rat Smoothened, are provided. Compositions including vertebrate Smoothened chimeras, nucleic acid encoding vertebrate Smoothened, and antibodies to vertebrate Smoothened, are also provided.Type: GrantFiled: September 30, 1996Date of Patent: November 23, 1999Assignee: Genentech, Inc.Inventors: Frederic J. de Sauvage, Arnon Rosenthal, Donna M. Stone
-
Patent number: 5965709Abstract: IgE antagonists comprising one or more of the Fc.sub..epsilon. RI receptor-binding determinant sites of human IgE are described. The disclosed antagonists include IgE variants, peptide antagonists, peptidomimetics and other small molecules. The antagonists are useful in raising and screening anti-IgE antibodies, in the isolation and purification of Fc.sub..epsilon. RI receptor, and in the treatment of allergic disease.Type: GrantFiled: April 21, 1994Date of Patent: October 12, 1999Assignee: Genentech, Inc.Inventors: Leonard G. Presta, Paula M. Jardieu
-
Patent number: 5851984Abstract: Uses for Wnt polypeptides in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for enhancing proliferation or differentiation of a hematopoietic stem/progenitor cell using a Wnt polypeptide, and optionally another cytokine, are described.Type: GrantFiled: August 16, 1996Date of Patent: December 22, 1998Assignee: Genentech, Inc.Inventors: William Matthews, Timothy W. Austin
-
Patent number: 5656273Abstract: This invention concerns a method for the prevention and treatment of parasitic infection by administering an IgE antagonists. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.Type: GrantFiled: April 14, 1995Date of Patent: August 12, 1997Assignee: Genentech, Inc.Inventors: Payman Amiri, Mary Haak-Frendscho, Paula M. Jardieu
-
Patent number: 5608078Abstract: Dipeptide compounds and analogs thereof having a phosphonomethyl moiety are disclosed. These compounds inhibit Endothelin Converting Enzyme and are thus useful in treating conditions responsive to inhibition of production of Endothelin.Type: GrantFiled: November 13, 1995Date of Patent: March 4, 1997Assignee: Merrell Pharmaceuticals Inc.Inventors: Hugues d'Orchymont, Marc Bigaud
-
Patent number: 5606108Abstract: The preferred oligomers of the present invention are polyureas having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. These oligomers are prepared by reacting an aromatic diamine with a difunctional electrophile, in the presence of an acid acceptor, in water as the solvent or water with up to about 1 mole of water immiscible cosolvent, at a temperature of from 0.degree. to 100.degree. C. and at a pH between about 7 to about 9. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.Type: GrantFiled: October 6, 1993Date of Patent: February 25, 1997Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical Co.Inventor: Michael J. Mullins
-
Patent number: 5593664Abstract: The present invention relates to the use of certain anionic polyamide and polyurea oligomers for inhibiting angiogenesis, and for their use in treating diseases associated with angiogenesis. These oligomers have a number average molecular weight (M.sub.n) less than 10,000, comprise recurring units coupled by carbonyl linking moieties and have predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium. The oligomers also have a preferably linear backbone and be be in their salt form, preferably wherein the salt is pharmaceutically acceptable.Type: GrantFiled: April 5, 1995Date of Patent: January 14, 1997Assignee: Merrell Pharmaceuticals Inc.Inventors: Paul S. Wright, Alan J. Bitonti
-
Patent number: 5571505Abstract: The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.Type: GrantFiled: May 19, 1995Date of Patent: November 5, 1996Assignees: The Dow Chemical Company, Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5547992Abstract: The oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of HSV and HCMV.Type: GrantFiled: March 21, 1995Date of Patent: August 20, 1996Assignees: The Dow Chemical Co., Merrell Pharmaceuticals Inc.Inventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5512177Abstract: The narrow poly- or mono-dispersed oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a recurring unit of from 3 to 50. These oligomers are water-soluble, preferably have a rigid backbone, have recurring units coupled by carbonyl linking moities which have anionic groups, display predominantly linear geometry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The narrow poly- or mono-dispersed oligomers are useful for the treatment and/or diagnosis of AIDS and/or ARC or HSV.Type: GrantFiled: November 22, 1993Date of Patent: April 30, 1996Assignees: The Dow Chemical Co., Merrell Dow Pharmaceuticals Inc.Inventors: Alan D. Cardin, Michael J. Mullins, William A. Fordyce, Thomas A. Chamberlin, Michael J. Fazio
-
Patent number: 5491136Abstract: The present invention is directed to a method of using a certain compounds which are 2,19-methyleneoxy or 2,19 methylenethio bridged steroids, and related steroidal compounds as inhibitors of the enzyme steroid aromarase, 19-hydroxylase and as treatment for various estrogen dependent/mediated disorders including hormonal dependent breast cancer.Type: GrantFiled: March 18, 1994Date of Patent: February 13, 1996Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Norton P. Peet, J. O'Neal Johnston, Joseph P. Burkhart
-
Patent number: 5486511Abstract: This invention is directed to 4-amino-17.beta.-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17.beta.-(cyclopropylylamino)androst-4-en-3-one and related compounds, a process for their synthesis, a pharmaceutical composition having C.sub.17-20 lyase and 5.alpha.-reductase inhibitory activity, the use of the present compounds as C.sub.17-20 lyase and 5.alpha.-reductase inhibitors and also to a method for using such compounds in the treatment of androgen and/or estrogen dependent disorders, including bengin prostatic hyperplasia, breast cancer and prostatic cancer. The 4-amino compounds are prepared by the reaction of the appropriate 4,5-epoxide with sodium azide in an inert solvent in the presence of a catalytic amount of strong acid under appropriate reaction conditions. Alternatively, the 4-amino compounds are prepared by first nitration and then reduction of the appropriate steroid under appropriate reaction conditions.Type: GrantFiled: May 2, 1994Date of Patent: January 23, 1996Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Philip M. Weintraub, Cynthia A. Gates, Michael R. Angelastro, Timothy T. Curran, J. O'Neal Johnston
-
Patent number: 5460807Abstract: The oligomers of the present invention are polyureas or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for inhibiting the proliferation of smooth muscle cell.Type: GrantFiled: June 15, 1993Date of Patent: October 24, 1995Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Alan D. Cardin, Steven J. Busch, Masayuki Mano
-
Patent number: 5436237Abstract: The present invention relates to 4-amino-.DELTA..sup.4 -steroids which are useful as inhibitors of 5.alpha.-reductase. The compounds are prepared by the reaction of an appropriate 4-azido steroid with triphenylphosphine in an aqueous inert solvent with heating.Type: GrantFiled: February 25, 1994Date of Patent: July 25, 1995Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Philip M. Weintraub, Joseph P. Burkhart, Thomas R. Blohm